=== SUMMARY ===
- The post analyzes Viridian Therapeutics ($VRDN) after strong Phase 3 data for a thyroid eye disease drug, highlighting a recent $350M capital raise at $17/share with institutions locked until $26, and a PDUFA catalyst on June 30.
- The author’s thesis is that the stock is trading below the institutional offering price ($16.89 vs $17.00), creating an arbitrage with a floor, and the upcoming FDA decision could drive the stock to analyst targets of $34+.
- Quality assessment: This is well-researched DD with specific data points (p<0.0001, offering details, convertible note conversion at $24.65, cash position), though written in a casual WSB style. The author has a large personal position ($30k+), adding conviction.
=== SENTIMENT ===
BULLISH
=== TRADE IDEAS ===
VRDN - LONG | confidence: 0.85 | sentiment: +0.80
Speaker: u/Buy-NVDA
Thesis:
1. THE FACT: Institutions bought shares at $17.00 in an upsized offering and are locked from selling until $26; stock currently trades at $16.89.
2. THE BRIDGE: This creates a “floor” below the offering price, and the June 30 PDUFA for veligrotug is a binary catalyst that could send the stock to $34+.
3. THE VERDICT: Buy the dip below institutional entry; the setup offers both downside protection (institutional floor) and upside optionality (FDA approval).
4. RISKS: FDA denial or delay on June 30; negative clinical or safety readouts; broader biotech selloff; dilution risk from the convertible notes (conversion at $24.65).
Timeframe: medium-term
Key Points:
- Buy below $17 institutional offering price
- PDUFA June 30 for veligrotug
- Best-in-class drug vs Amgen’s Tepezza
- $1.1B cash buffer post-raise
- Convertible notes bet on $25+
Оценка15
Комментарии17
% апвоутов93%
▶ Полный текст поста
I’m just college student who has spent more time reading biotech clinical trial protocols than studying for my exams. I’m $30k+ deep into this. I am a regard, and this is a casino. And yeah this is written by ai but its my research im lazy and not getting paid to write this sue me.
**The TL;DR**
Viridian Therapeutics (**$VRDN**) just dropped god-tier Phase 3 data (REVEAL-2), gap-up pumped the stock, and then immediately "upsized" a capital raise to build a **$1.1 BILLION liquid to push their new drug**. The banks just bought millions of shares at **$17.00 and cant sell until $26**. Right now, the stock is trading at **$16.89**. You can literally buy the dip cheaper than the billionaires did.
**1. The Data:**
Last week, VRDN released results for their TED drug (Chronic Thyroid Eye Disease).
• **The Result:** p < 0.0001. They didn't just beat the placebo; they vaporized it.
• **The Competition:** They are coming for Amgen’s Tepezza (a multi-billion dollar monopoly). VRDN’s drug is safer, has way fewer side effects (no hearing loss), and is building an at-home injector so patients don't have to sit in a hospital chair for 4 hours.
• **The Outcome:** This is "Best-in-Class" medicine. Period.
**2. The "Institutional Floor" (Buying Below the Banks)**
• **The Offering:** They just closed an upsized **$350 MILLION** raise today.
• **The Price:** The institutions (the people who actually know how to read balance sheets) just agreed to buy at **$17.00**.
• **The Arbitrage:** We are currently trading **BELOW** the offering price. Usually, retail is the "exit liquidity" for the banks. This time, the banks are the floor for us.
• **The Convertible Clue:** They issued notes with a conversion price of **$24.65**. The banks are literally betting $225M that this stock hits $25+ in the near future.
**3. The Catalyst: JUNE 30 MOONSHOT** 🌙
The REVEAL-2 data was just the appetizer. The **real** play is the **June 30 PDUFA date** for their lead drug, **Veligrotug**.
• **Priority Review:** The FDA is fast-tracking this.
• **The Setup:** With $1.1B in cash, VRDN is "uncrashable." They are fully funded for a global launch. If the FDA says "Yes" on June 30, this stock doesn't just go to $20; it hits the analyst targets of **$34.00+**.
Check my profile if u think this is my first time spotting a moon shot. Will answer any questions in the comments.
Institutions bought shares at $17.00 in an upsized offering and are locked from selling until $26; stock currently trades at $16.89. This creates a “floor” below the offering price, and the June 30 PDUFA for veligrotug is a binary catalyst that could send the stock to $34+. Buy the dip below institutional entry; the setup offers both downside protection (institutional floor) and upside optionality (FDA approval). FDA denial or delay on June 30; negative clinical or safety readouts; broader biotech selloff; dilution risk from the convertible notes (conversion at $24.65).